Estudo laboratorial mostra que a vacinação heteróloga AstraZeneca/Pfizer produz uma forte resposta imune contra a variante delta do SARS-CoV-2.

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination – The Lancet

Conteúdos relacionados:

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (vários artigos sobre o tema)

Comentário no Twitter (fio – clique para saber mais)

Mix and match vaccines, AZ then mRNA (@BioNTech_Group) achieves a very strong immune response against the Delta variant.
This is the 1st report to look at mix vs Delta, specifically.https://t.co/6N46cUh8HW @TheLancet pic.twitter.com/cvlHp2XtXJ

— Eric Topol (@EricTopol) August 17, 2021